ALK-Abelló A/S (ALK-B.CO)

DKK 161.5

(5.56%)

Net Income Summary of ALK-Abelló A/S

  • ALK-Abelló A/S's latest annual net income in 2023 was 486 Million DKK , up 45.07% from previous year.
  • ALK-Abelló A/S's latest quarterly net income in 2024 Q2 was 201 Million DKK , down -13.36% from previous quarter.
  • ALK-Abelló A/S reported an annual net income of 335 Million DKK in 2022, up 52.97% from previous year.
  • ALK-Abelló A/S reported an annual net income of 219 Million DKK in 2021, up 776.0% from previous year.
  • ALK-Abelló A/S reported a quarterly net income of 201 Million DKK for 2024 Q2, down -13.36% from previous quarter.
  • ALK-Abelló A/S reported a quarterly net income of 66 Million DKK for 2023 Q2, down -59.51% from previous quarter.

Annual Net Income Chart of ALK-Abelló A/S (2023 - 2002)

Historical Annual Net Income of ALK-Abelló A/S (2023 - 2002)

Year Net Income Net Income Growth
2023 486 Million DKK 45.07%
2022 335 Million DKK 52.97%
2021 219 Million DKK 776.0%
2020 25 Million DKK 150.0%
2019 -50 Million DKK 70.59%
2018 -170 Million DKK -7.59%
2017 -158 Million DKK -158.52%
2016 270 Million DKK -21.51%
2015 344 Million DKK 90.06%
2014 181 Million DKK 196.72%
2013 61 Million DKK 12.96%
2012 54 Million DKK -73.0%
2011 200 Million DKK 56.25%
2010 128 Million DKK 8.47%
2009 118 Million DKK 24.21%
2008 95 Million DKK -32.14%
2007 140 Million DKK 483.33%
2006 24 Million DKK -99.44%
2005 4.3 Billion DKK 0.0%
2004 - DKK 0.0%
2003 - DKK 0.0%
2002 - DKK 0.0%

Peer Net Income Comparison of ALK-Abelló A/S

Name Net Income Net Income Difference
Bavarian Nordic A/S 1.47 Billion DKK 67.055%
Genmab A/S 4.35 Billion DKK 88.833%
Gubra A/S -44.52 Million DKK 1191.546%
Novo Nordisk A/S 83.68 Billion DKK 99.419%
Orphazyme A/S -26.04 Million DKK 1965.786%
Pharma Equity Group A/S -24.6 Million DKK 2074.887%
Zealand Pharma A/S -703.73 Million DKK 169.06%